Immunogenicity of a yeast-derived hepatitis B vaccine in hemodialysis patients.
In a multicenter study of hemodialysis patients in Spain, the immunogenicity of a yeast-derived recombinant deoxyribonucleic acid hepatitis B vaccine was evaluated. Two different vaccination schedules were examined: zero, one, two, six months and zero, one, two, 12 months. Two different dose levels (20 micrograms and 40 micrograms) were also compared. No serious adverse effects were reported by any of the vaccinees; the most frequently reported reaction was soreness at the injection site. This study also indicated that higher concentrations of antibodies are attained when more frequent doses of vaccine are administered. The yeast-derived vaccine produced an immune response similar to that of the plasma-derived vaccines.
Bruguera
M
M
Servicio de Hepatología, Hospital Clínico, Barcelona, Spain.
Cremades
M
M
Rodicio
J L
JL
Alcazar
J M
JM
Oliver
A
A
Del Rio
G
G
Esteban-Mur
R
R
D002986:Clinical Trials as Topic; D004342:Drug Hypersensitivity / Q000276:immunology*; D006508:Hepatitis Antibodies / Q000032:analysis*; D006509:Hepatitis B / Q000276:immunology* / Q000517:prevention & control; D017325:Hepatitis B Vaccines; D006801:Humans; D015337:Multicenter Studies as Topic; D006435:Renal Dialysis; D014761:Viral Hepatitis Vaccines / Q000276:immunology*
D006508:Hepatitis Antibodies; D017325:Hepatitis B Vaccines; D014761:Viral Hepatitis Vaccines